The delay hides outside the model.
In September 2025, the FDA approved an updated label for Krystal Biotech’s beremagene geperpavec-svdt (B-VEC/YJUVEK), ...
Recently published Epidermolysis Bullosa Market Insights report includes a comprehensive understanding of current treatment practices, epidermolysis bullosa emerging drugs, market share of individual ...
The growth of the epidermolysis bullosa market is expected to be mainly driven by increasing prevalence, patient awareness, label expansion of approved therapies, high cost of therapies, and ...